scispace - formally typeset
Journal ArticleDOI

Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine, Endocrinology, Pathology, Biology, Endocrine Surgery and Head and Neck Surgery.

Reads0
Chats0
TLDR
Slimane Zerdoud a, Anne-Laure Giraudet b, Sophie Leboulleux c, Laurence Leenhardt d, Stéphane Bardet e, Jérôme Clerc f, Marie-Elisabeth Toubert g, Abir Al Ghuzlan.
Abstract
Slimane Zerdoud a, Anne-Laure Giraudet b, Sophie Leboulleux c, Laurence Leenhardt d, Stéphane Bardet e, Jérôme Clerc f, Marie-Elisabeth Toubert g, Abir Al Ghuzlan h, Pierre-Jean Lamy i,j, Claire Bournaud k, Isabelle Keller l, Frédéric Sebag m, Renaud Garrel n, Eric Mirallié o, Lionel Groussin p, Elif Hindié q,∗, David Taïeb r,∗ a Service de médecine nucléaire, institut universitaire du cancer Toulouse oncopole, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex 9, France b Médecine nucleaire, centre LUMEN, curiethérapie, thyroïde, tumeurs endocrines, centre de lutte contre le cancer Léon-Berard, 28, rue Laennec, 69008 Lyon, France c Service de médecine nucléaire et cancérologie endocrinienne Gustave-Roussy, université Paris Saclay, 114, rue Edouard-Vaillant, 94805 Villejuif, France d Unité thyroïde tumeurs endocrines, institut E3M, hôpital La Pitié-Salpêtrière, 83, boulevard de l’Hôpital, 75013 Paris, France e Service de médecine nucléaire et UCP thyroïde, centre François-Baclesse, 3, avenue Général-Harris, 14076 Caen cedex 05, France f Service de médecine nucléaire, groupe hospitalier Paris Centre, AP–HP, 27, rue du Faubourg-Saint-Jacques, 75679 Paris cedex 14, France g Service de médecine nucléaire, hôpital Saint-Louis, AP–HP, 1, avenue Claude-Vellefaux, 75475 Paris cedex 10, France h Département de biologie et de pathologie médicales Gustave-Roussy, 39, rue Camille-Desmoulins, 94805 Villejuif, France i Laboratoire d’oncologie moléculaire, institut médical d’analyse génomique, Labosud, 141, avenue Paul-Bringuier, 34080 Montpellier, France j Unité de recherche clinique, clinique Beau-Soleil, 119, avenue de Lodeve, 34070 Montpellier, France k Service de médecine nucléaire, hospices civils de Lyon, groupement hospitalier Est, 28, avenue Doyen-Lépine, 69677 Bron cedex, France l Service de médecine nucléaire, hôpitaux universitaires Est Parisien, hôpital Saint-Antoine, AP–HP, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France m Service de chirurgie endocrinienne, université Aix-Marseille, CHU de la Timone, 264, rue Saint-Pierre, 13005 Marseille, France n Département ORL et chirurgie cervico faciale, pole neuroscience tête et cou, hôpital Gui-de-Chauliac, CHU de Montpellier, 80, rue Fliche, 34295 Montpellier, France o Service de chirurgie endocrinienne et digestive, CHU de Nantes, 1, place Alexis-Ricordeau, 44093 Nantes, France p Service d’endocrinologie et maladies métaboliques, hôpital Cochin, AP–HP, 123, boulevard du Port-Royal, 75014 Paris, France q Service de médecine nucléaire, hôpital Haut-Lévêque, université de Bordeaux, CHU de Bordeaux, avenue Magellan, 33604 Pessac, France r Service central de biophysique et de médecine nucléaire, université Aix-Marseille, CHU de la Timone, 264, rue Saint-Pierre, 13005 Marseille cedex 05, France

read more

Citations
More filters
Journal ArticleDOI

The cholesterol-derived metabolite dendrogenin A functionally reprograms breast adenocarcinoma and undifferentiated thyroid cancer cells.

TL;DR: The re-differentiation of breast and thyroid cancer cells by DDA, is associated with the recovery of functional NIS expression and involves an LXR-dependent mechanism, which open new avenues of research for the diagnosis of thyroid cancers as well as the development of new therapeutic approaches for radioiodine refractory thyroid cancers.
Journal ArticleDOI

Predicting recurrence of papillary thyroid cancer using the eighth edition of the AJCC/UICC staging system

TL;DR: The hypothesis of this study was that the eighth edition of the AJCC system can be used in this novel way to predict survival in papillary thyroid cancer.
Journal ArticleDOI

A Matter of Controversy: Is Radioiodine Therapy Favorable in Differentiated Thyroid Carcinoma?

TL;DR: Why the use of radioiodine therapy in more than only high-risk patients should be advocated, including tumor stage, extent of surgery, tumor biology, clinical and imaging data, life expectancy, and patient preferences.
Journal ArticleDOI

Risk of recurrence in patients with papillary thyroid carcinoma and minimal extrathyroidal extension not treated with radioiodine.

TL;DR: The results suggest that patients with mETE and without other adverse features, who have low nonstimulated Tg and negative neck US after thyroidectomy, do not require ablation with RAI.
References
More filters
Journal ArticleDOI

European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium

TL;DR: European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium Furio Pacini, Martin Schlumberger, Henning Dralle, Rossella Elisei, Johannes W A Smit, Wilmar Wiersinga and the European Thyroid Cancer Taskforce Section of Endocrinology and Metabolism are presented.
Journal ArticleDOI

Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer

TL;DR: The approach to treatment of papillary and follicular cancer is usually very similar, and DTC is more likely to be completely resected and ablated with iodine-131 (I), an approach that has become more popular in the past several decades when discovered at an early stage.
Related Papers (5)